- Home
- AGO vs VKTX Comparison
AGO vs VKTX Comparison
Compare AGO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGO
- VKTX
- Stock Information
- Founded
- AGO 2003
- VKTX 2012
- Country
- AGO Bermuda
- VKTX United States
- Employees
- AGO N/A
- VKTX N/A
- Industry
- AGO Property-Casualty Insurers
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- AGO Finance
- VKTX Health Care
- Exchange
- AGO Nasdaq
- VKTX Nasdaq
- Market Cap
- AGO 3.9B
- VKTX 3.8B
- IPO Year
- AGO 2004
- VKTX 2015
- Fundamental
- Price
- AGO $82.58
- VKTX $34.37
- Analyst Decision
- AGO Buy
- VKTX Strong Buy
- Analyst Count
- AGO 2
- VKTX 13
- Target Price
- AGO $98.50
- VKTX $85.54
- AVG Volume (30 Days)
- AGO 254.5K
- VKTX 4.9M
- Earning Date
- AGO 11-06-2025
- VKTX 10-22-2025
- Dividend Yield
- AGO 1.65%
- VKTX N/A
- EPS Growth
- AGO N/A
- VKTX N/A
- EPS
- AGO 9.06
- VKTX N/A
- Revenue
- AGO $891,000,000.00
- VKTX N/A
- Revenue This Year
- AGO N/A
- VKTX N/A
- Revenue Next Year
- AGO N/A
- VKTX N/A
- P/E Ratio
- AGO $9.09
- VKTX N/A
- Revenue Growth
- AGO 3.01
- VKTX N/A
- 52 Week Low
- AGO $74.09
- VKTX $18.92
- 52 Week High
- AGO $96.50
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- AGO 51.51
- VKTX 59.51
- Support Level
- AGO $81.23
- VKTX $30.86
- Resistance Level
- AGO $83.39
- VKTX $36.11
- Average True Range (ATR)
- AGO 1.63
- VKTX 2.08
- MACD
- AGO 0.08
- VKTX 0.05
- Stochastic Oscillator
- AGO 59.40
- VKTX 59.01
About AGO Assured Guaranty Ltd.
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.